Scabies foam - Stiefel Laboratories/Foamix
Latest Information Update: 05 Jun 2013
At a glance
- Originator Foamix; Stiefel Laboratories
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Scabies
Most Recent Events
- 05 Jun 2013 Discontinued - Preclinical for Scabies in USA (Topical)
- 19 Oct 2005 Preclinical trials in Scabies in USA (Topical)